Akouos IPO Presentation Deck

Internal Manufacturing Capabilities May Provide Competitive Advantage 42 Expertise in Gene Therapy and Gene Editing Building In-House cGMP Manufacturing Capabilities Current Supply from a Well-Established CMO Expertise covers development from vector design through drug product manufacture Developing scalable manufacturing capabilities, which may allow for significant control over process development timelines and cost • Internal capabilities to process gene therapy batches to support activities through Phase 1/2 clinical trials Plans to leverage single use, disposable, closed system operations aligned to genetic medicine platform to promote both flexibility and cost-effectiveness Internal analytical and process development • 250 L single-use bioreactor system using suspension HEK293 cells Agreement with Lonza, which has performed toxicology manufacturing supply for AK-OTOF program and will conduct CGMP manufacturing to support clinical development AKOUOS CONFIDENTIAL

View entire presentation